NEW YORK--(BUSINESS WIRE)--Feb. 9, 2006--ZIOPHARM Oncology, Inc. (OTC BB: ZIOP), announced today a second organic arsenic case has been issued as U.S. Patent No. 6995188. The patent issue follows an announcement of a notice of allowance in mid-January. The patent provides further coverage of cancer treatment using organic arsenic, including ZIO-101, in combination with other agents or therapies.
